Subscribe: Market Wire - Pharmaceuticals and Biotech: Biotech
http://img.marketwire.com/rss/mwPBBI.rss
Added By: Feedage Forager Feedage Grade A rated
Language: English
Tags:
announced  clinical trial  clinical  company  european  january  marketwired january  marketwired  otcqb  pharma  today announced  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Biotech

Marketwired - Biotech



Marketwired - Biotech



Last Build Date: Wed, 17 Jan 2018 09:53:05 EST

Copyright: Copyright: (C) Marketwired
 



Rennova Health's Epic Reference Labs Receives Accreditation From College of American Pathologists

Wed, 17 Jan 2018 09:20:00 EST

WEST PALM BEACH, FL--(Marketwired - January 17, 2018) - Rennova Health, Inc. (OTCQB: RNVA), (OTCQB: RNVAW) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, that opened its first rural hospital in Oneida, Tenn. in August 2017, announces that its flagship Laboratory, EPIC Reference Labs, Inc. (EPIC) has successfully met the Laboratory Accreditation Program Standards for Accreditation from the College of American Pathologists (CAP). EPIC has been operating as a urine toxicology testing laboratory in Riviera Beach, Fla. since 2015.




Leading Leukemia Experts Join Moleculin's Science Advisory Board

Wed, 17 Jan 2018 08:30:00 EST

HOUSTON, TX--(Marketwired - January 17, 2018) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced the expansion of its Science Advisory Board to include Drs. Jorge Cortes and Elihu Estey.




Neptune présente ses recommandations aux consultations particulières sur le projet de loi 157 à l'Assemblée nationale

Wed, 17 Jan 2018 08:00:00 EST

Une entreprise québécoise à l'expertise unique dans l'extraction d'huile a des visées mondiales en matière de cannabis




Neptune makes its recommendations on Bill 157 special consultations at the National Assembly

Wed, 17 Jan 2018 08:00:00 EST

A Quebec company with unique expertise in oil extraction has global objectives for cannabis




Ceapro to Present at Noble Capital Markets' 14th Annual Investor Conference

Wed, 17 Jan 2018 08:00:00 EST

- Presentation with live video webcast on Tuesday, January 30th at 2:00 p.m. EST -




Trillium Therapeutics Enhances Senior Management Team to Support Further Clinical Development of TTI-621

Wed, 17 Jan 2018 07:00:00 EST

TORONTO, ONTARIO--(Marketwired - Jan. 17, 2018) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the following key additions to its leadership team:




Oncolytics Biotech(R) Announces Abstract for Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas

Tue, 16 Jan 2018 17:00:00 EST

CALGARY, AB and SAN DIEGO, CA--(Marketwired - January 16, 2018) - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), a biotech company developing REOLYSIN®, also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn "cold" tumors "hot", today announced that the abstract relating to the previously announced poster presentation highlighting results from the REO 024 study was published by the 2018 Gastrointestinal Cancers Symposium sponsored by ASCO. The conference takes place January 18 - 20, 2018, in San Francisco.




EnWave Provides Corporate Update and Announces Amendment to its Consulting Agreement with Adelaide Capital Markets

Tue, 16 Jan 2018 09:00:00 EST




Avalon GloboCare Appoints Dr. Bo Chen as Vice President of Mergers & Acquisitions to Accelerate Growth

Tue, 16 Jan 2018 08:00:00 EST

FREEHOLD, NJ--(Marketwired - January 16, 2018) - Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today that the Company has appointed Dr. Bo Chen as Vice President, Business Development to lead mergers & acquisitions activity. Dr. Chen will focus on executing Avalon's acquisition strategy by helping identify companies with a strategic fit within the cell therapeutics, cell diagnostics and rehabilitation sectors.




Tetra Bio-Pharma Receives Approval from Health Canada of its Phase 1 Clinical Trial with PPP005 (Cannabis Oil)

Tue, 16 Jan 2018 08:00:00 EST

OTTAWA, ONTARIO--(Marketwired - Jan. 16, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its cannabis oil PPP005.




CTD Holdings' European Clinical Trial Adopted by National Institute for Health Research of England

Tue, 16 Jan 2018 08:00:00 EST

Collaboration Will Provide Infrastructure Support to Study




Novoheart Files Patent Application on Three-Tier Drug Screening System After Successful Collaboration Contract with Global Pharma Company

Tue, 16 Jan 2018 07:30:00 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 16, 2018) - Novoheart ("Novoheart" or the "Company") (TSX VENTURE:NVH) today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a three-tiered drug screening system with enhanced capability, sensitivity and accuracy for detecting pharmacological effects on heart contractility that cannot be achieved with conventional models. The application resulted from the Company's collaborative contract with a multi-national global pharma company ("Pharma"). The completion of this contract also led to a subsequent income-generating contract with the same Pharma to build a cardiac disease model using the MyHeartT Platform. Further details on both will be announced separately.




BioVie Reviews Key Accomplishments in 2017 and Updates on Phase 2a Clinical Trial Progress

Tue, 16 Jan 2018 07:00:00 EST

BEVERLY, MA--(Marketwired - January 16, 2018) - BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease, today reviewed key milestones achieved over the past year and provided a general update on the progress of its mid-stage (Phase 2a) clinical trial of BIV201 in refractory ascites patients.




Imagin Medical Recruits Senior Healthcare Industry CFO

Mon, 15 Jan 2018 16:07:03 EST

VANCOUVER, BC and BOSTON, MA--(Marketwired - January 15, 2018) - Imagin Medical (CSE: IME) (CSE: IME.CN) (CNSX: IME) (OTC PINK: IMEXF) (FRANKFURT: DPD2) (STUT: DPD2) (the "Company") announced today that it hired John Vacha as the Company's new CFO.




Prevtec Microbia reçoit une autorisation de mise en marché du Coliprotec® F4 de la part du USDA

Mon, 15 Jan 2018 10:15:28 EST

Un financement d'un important fonds d'investissement canadien jusqu'à hauteur de CAD$10 millions est obtenu




Prevtec Microbia Receives Market Authorization from USDA for Coliprotec® F4

Mon, 15 Jan 2018 10:14:18 EST

Up to CAD$10 million in Financing Secured from a Large Canadian Investment Fund




EnWave Signs Equipment Purchase Agreement with Bare Foods Co.

Mon, 15 Jan 2018 09:00:00 EST




ENRICH in the USA Network and West Coast Hub Is Launched

Mon, 15 Jan 2018 03:01:00 EST

SAN FRANCISCO, CA--(Marketwired - January 15, 2018) - The European Business and Innovation Centre Network (EBN) and the International Business Innovation Association (InBIA) are pleased to announce the inaugural program of the West Coast Hub of ENRICH in the USA (European Network of Research and Innovation Centers and Hubs). This program, which is hosted by the European American Enterprise Council (EAEC), is uniquely designed to help European researchers and innovators in the US.




Zecotek Increases Non-Brokered Private Placement

Fri, 12 Jan 2018 18:00:00 EST

VANCOUVER, BC--(Marketwired - January 12, 2018) -




Aequus Announces Proposed $300,000 Equity Financing

Thu, 11 Jan 2018 08:30:00 EST

VANCOUVER, BC--(Marketwired - January 11, 2018) -

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES